A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data
Objective: The study will evaluate the efficacy and safety of prasinezumab in individuals with early-stage Parkinson's disease (PD) on stable symptomatic therapy. Background: Available treatments…Analysis of the network of genes related to Parkinson’s and identification of key proteins
Objective: Parkinson's disease (PD) is one of the increasing age-related diseases with no definite treatment. PD is considered as a disorder with genetic and non-genetic…Neuroprotective effects of oral consumption of Bifidobacterium lactis and Lactobacillus acidophilus probiotics on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropytide-induced Parkinson’s Disease mouse model
Objective: To explore the effects of probiotics strains Bifidobacterium animalis subsp. lactis (B.lactis) and Lactobacillus acidophilus (L.acidophilus) on the inflammation of gut-brain axis and degeneration…Salivary α-synuclein in Parkinson’s disease – a pilot study
Objective: The aim of our study was to measure total salivary α-synuclein in Parkinson´s disease (PD) patients to assess its potential as a biomarker of…A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development
Objective: The objective of these studies is to develop a tissue engineered nigrostriatal system involving human dopaminergic and striatal cells to recapitulate many of the…The Synuclein-One Study: Detection of Cutaneous Phosphorylated alpha-synuclein for the Diagnosis of the Synucleinopathies
Objective: The Synuclein-One study is an NIH-funded 30-site, multicenter trial of 428 patients with synucleinopathies including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple…Protective effect and mechanism of TREM2 in Parkinson’s disease with cognitive impairment
Objective: this study explored whether TREM2 plays a protective role in PD with cognitive impairment by promoting the activation of DAM. Background: The latest research…Development of therapeutic substances for the disassembly of α-synuclein aggregates as disease-modifying treatment of synucleinopathies
Objective: Development of high-affinity ligands to α-synuclein (α-syn) for a therapeutic approach aiming for the disassembly of α-syn aggregates as a disease-modifying treatment of synucleinopathies.…Distinct characteristics of gut microbiome in patients with Parkinson’s disease according to the presence of premotor REM sleep behavior disorders
Objective: We aimed to investigate whether the composition and function of gut microbiome obtained from shotgun metagenomic sequencing are different between Parkinson’s disease (PD) patients…Investigation of Modifiers of β-Glucocerebrosidase in Cell Models of Parkinson’s Disease
Objective: We firstly aim to identify modifiers of β-glucocerebrosidase (GCase) activity and expression in Parkinson’s disease (PD) relevant cell models. We secondly aim to ascertain…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 60
- Next Page »